title: UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis.
abstract: The UK Scleroderma Study Group developed guidelines on the diagnosis and management of scleroderma renal crisis (SRC) based on best available evidence and clinical experience. SRC is characterised by the acute onset of severe hypertension and acute kidney injury. Current strategies to reduce the associated morbidity and mortality include identifying at risk patients to aid early diagnosis. ACE inhibitor therapy should be lifelong in all patients, regardless of whether they require renal replacement therapy. Patients with SRC may recover renal function up to 3 years after the crisis, most often within 12 to 18 months.
authors.affiliation: Centre for Rheumatology, Royal Free London and UCL Division of Medicine, London, UK.
authors.forename: Bernadette M
authors.initials: BM
authors.lastname: Lynch
authors.affiliation: Centre for Rheumatology, Royal Free London and UCL Division of Medicine, London, UK.
authors.forename: Edward P
authors.initials: EP
authors.lastname: Stern
authors.affiliation: Centre for Rheumatology, Royal Free London and UCL Division of Medicine, London, UK.
authors.forename: Voon
authors.initials: V
authors.lastname: Ong
authors.affiliation: Department of Renal Medicine, Royal Free London NHS Foundation Trust, London, UK.
authors.forename: Mark
authors.initials: M
authors.lastname: Harber
authors.affiliation: Department of Renal Medicine, Royal Free London NHS Foundation Trust, London, UK.
authors.forename: Aine
authors.initials: A
authors.lastname: Burns
authors.affiliation: Centre for Rheumatology, Royal Free London and UCL Division of Medicine, London, UK. c.denton@ucl.ac.uk.
authors.forename: Christopher P
authors.initials: CP
authors.lastname: Denton
mesh_terms: D058186:Acute Kidney Injury / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage; D000927:Anticonvulsants / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage; D032921:Consensus; D019091:Critical Pathways / Q000592:standards; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine / Q000592:standards; D006801:Humans; D006973:Hypertension / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D009398:Nephrology / Q000592:standards*; D011237:Predictive Value of Tests; D017582:Renal Replacement Therapy / Q000592:standards*; D012219:Rheumatology / Q000592:standards*; D012307:Risk Factors; D012595:Scleroderma, Systemic / Q000150:complications* / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000927:Anticonvulsants; D000959:Antihypertensive Agents